BPC June 23 update

F-star Therapeutics FSTX Acquired by invoX; RedHill RDHL 1Q Earnings

Pre-Market Updates

Yesterday's BIOrdle ticker was LJPC. La Jolla Pharmaceutical Company (NASDAQ: LJPC) is a biotech that has approved drugs to treat complicated intra-abdominal infections (cIAI) and increase blood pressure in adults with septic or other distributive shock. La Jolla has a revenue guidance of $34,137,000. Shares closed yesterday down -0.3% at $3.38.

__________________________

RedHill Biopharma Ltd. (NASDAQ: RDHL) reported its first quarter 2022 financial results and operational highlights. Redhill reported sales of $18.2 million versus $22.1 million in the prior quarter. They also noted that it expects to generate operational cost savings of approximately $50 million over the next 18 months.

F-star Therapeutics, Inc. (NASDAQ: FSTX) will be acquired by invoX Pharma for $7.12 per share with a total deal value of approximately $161 million.

Applied Therapeutics, Inc. (NASDAQ: APLT) priced its public offering of 20 million shares and 10 million pre-funded warrants. The gross proceeds are expected to be $30 million.

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) priced its public offering of 7,868,854 shares and pre-funded warrants at $30.50 per share and $30.4999 per pre-funded warrant. The gross proceeds are expected to be approximately $250 million.

Aura Biosciences Inc. (NASDAQ: AURA) reported results from its Phase 1/2 trial of AU-011by intravitreal administration noting that in a retrospective, matched case control study the visual acuity of patients following treatment with plaque radiotherapy compared with prospective data on visual acuity in subjects with early-stage choroidal melanoma in the treatment group.

Zai Lab Ltd (NASDAQ: ZLAB) announced voluntary conversion of its secondary listing status to dual-primary listing on HK stock exchange will become effective on June 27, 2022.

Soligenix, Inc. (NASDAQ: SNGX) announced preclinical data of its bivalent, thermostabilized vaccine formulated in a single vial in use with non-human primates (NHPs), noting 100% protection against lethal Marburg marburgvirus (MARV).

The World Health Organization will convene an emergency committee today to discuss the monkeypox outbreak and assess its level of international concern. SIGA Technologies, Inc. (NASDAQ: SIGA), Co-Diagnostics, Inc. (NASDAQ: CODX) and GeoVax Labs, Inc. (NASDAQ: GOVX) both are trading higher in the premarket, due to their exposure to the monkeypox indication. SIGA Technologies, Inc. also announced $13 million of procurement orders for oral TPOXX (tecovirimat) in response to the monkeypox outbreak.

Pre-Market Advancers

CompanyPriceChange
TALS
Talaris Therapeutics Inc.
$1.01 +1.01  +100%
AKUS
Akouos Inc.
$1.01 +1.01  +100%
QNRX
Quoin Pharmaceuticals Ltd.
$1.01 +1.01  +100%
BBI
Brickell Biotech, Inc.
$1.01 +1.01  +100%
AKBA
Akebia Therapeutics Inc.
$1.01 +1.01  +100%
ALNA
Allena Pharmaceuticals Inc.
$1.01 +1.01  +100%
PRVB
Provention Bio Inc.
$1.01 +1.01  +100%
IVC
Invacare Corporation
$1.01 +1.01  +100%
ENSC
Ensysce Biosciences Inc.
$1.01 +1.01  +100%
BNTC
Benitec Biopharma Inc.
$1.01 +1.01  +100%

Pre-Market Decliners

CompanyPriceChange
CADL
Candel Therapeutics Inc.
$1.01 -1.01  -100%
CLVS
Clovis Oncology Inc.
$1.01 -1.01  -100%
ENDP
Endo International plc
$1.01 -1.01  -100%
TYRA
Tyra Biosciences Inc.
$1.01 -1.01  -100%
CTKB
Cytek Biosciences Inc.
$1.01 -1.01  -100%
BLTE
Belite Bio Inc
$1.01 -1.01  -100%
MREO
Mereo BioPharma Group plc
$1.01 -1.01  -100%
CRTX
Cortexyme Inc.
$1.01 -1.01  -100%
PULM
Pulmatrix Inc.
$1.01 -1.01  -100%
RXST
RxSight Inc.
$1.01 -1.01  -100%